Evidence map›Paper›PMID 34301236›Full record

ArticleBMC biotechnology2021

Mapping the molecular basis for growth related phenotypes in industrial producer CHO cell lines using differential proteomic analysis.

Laura Bryan, Michael Henry, Ronan M Kelly, Christopher C Frye, Matthew D Osborne, Martin Clynes, Paula Meleady

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Laura BryanNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. laura.bryan2@mail.dcu.ie.
Michael HenryNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Ronan M KellyEli Lilly and Company, LTC-North, 1200 Kentucky Avenue, Indianapolis, IN, 46225, USA.
Christopher C FryeEli Lilly and Company, LTC-North, 1200 Kentucky Avenue, Indianapolis, IN, 46225, USA.
Matthew D OsborneEli Lilly, Kinsale Limite, Cork, Ireland.
Martin ClynesNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Paula MeleadyNational Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Dublin City University · IEEli Lilly (United States) · USEli Lilly (Ireland) · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ability to achieve high peak viable cell density earlier in CHO cell culture and maintain an extended cell viability throughout the production process is highly desirable to increase recombinant protein yields, reduce host cell impurities for downstream processing and reduce the cost of goods. In this study we implemented label-free LC-MS/MS proteomic profiling of IgG4 producing CHO cell lines throughout the duration of the cell culture to identify differentially expressed (DE) proteins and intracellular pathways associated with the high peak viable cell density (VCD) and extended culture VCD phenotypes.

resultsWe identified key pathways in DNA replication, mitotic cell cycle and evasion of p53 mediated apoptosis in high peak VCD clonally derived cell lines (CDCLs). ER to Golgi vesicle mediated transport was found to be highly expressed in extended culture VCD CDCLs while networks involving endocytosis and oxidative stress response were significantly downregulated.

conclusionThis investigation highlights key pathways for targeted engineering to generate desirable CHO cell phenotypes for biotherapeutic production.

Indexed as

Cell ProliferationAnimalsCell CycleCHO CellsChromatography, LiquidCricetinaeCricetulusImmunoglobulin GPhenotypeProteinsProteomeProteomicsTandem Mass SpectrometryImmunoglobulin GProteinsProteomeCell specific productivity (Qp)Chinese hamster ovary (CHO) cellsLabel free quantitative proteomicsViable cell density (VCD) biopharmaceuticals

Identifiers

PMID34301236
PMCPMC8305936
OpenAlexW3184947190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.